Searched for
RANBAXY SHANGHVI
Sun Pharma to acquire Organon for $11.75 billion in India’s biggest pharma dealSun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acq...- Sun's strong gravity helps India Inc's pullSun Pharma has expanded its horizons by acquiring Organon, a notable New Jersey pharmaceutical firm. This strategic acquisition fortifies S...
- Sun Pharma: How a small Kolkata trader became a global buyout artistSun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continu...
- ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till dateUS company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...
- With Sun Pharma set for its worst decline, Dilip Shanghvi faces his greatest testHis relentless drive has helped make Sun India’s biggest drugmaker and best performing stock over 20 years - and Shanghvi the country’s 2nd...
- Making Ranbaxy units cGMP compliant time consuming: Sun PharmaThe company expects to complete the remediation steps in at least one of these facilities in this fiscal, Sun Pharma Managing Director Dili...
- Sun Pharma may discontinue some non-strategic businessesDilip Shanghvi said the company expects to incur certain integration charges in order to generate long-term synergies from the merger (with...
- Yashwant Mahadik to lead Sun Pharma's HR teamMahadik, 48, was senior vice president - global head of human resources business, transformation, IT and operations of Philips.
- Focus on getting Ranbaxy's plants USFDA nod one at a time: Sun PharmaSun Pharma, which acquired Ranbaxy in a $4 bn deal, feels it is important for the merged entity to "re-establish" the trust between Ranbaxy...
- Open to acquisitions but selective with targets: Sun PharmaSun Pharma says it is open to further acquisitions but will consider only targets "which will not require significant amount of management ...
- Dilip Shanghvi, the self-made billionaire and Sun Pharma MD who hates limelightThe founder of Sun Pharma says far from being happy with the tag, he's not at all comfortable with the kind of attention it has triggered.
- No role for a few senior Ranbaxy execs in merged entity, says Dilip ShanghviThe announcement, however, spells uncertainty for a few executives of Ranbaxy who have no role in the merged entity, Sun Pharma’s Dilip Sha...
- Sun Pharma to delist Ranbaxy post $4-bn merger; swap ratio set at 8:10Sun Pharma in a filing to BSE said that Ranbaxy shareholders will get 8 shares of Sun Pharma for every 10 stocks they hold. Both stocks end...
- Sun Pharma executives bag top slots in company after Ranbaxy mergerMost executives from Ranbaxy's earlier team have already left the company in past one year.
- ET Awards 2014: Sun Pharma's Dilip Shanghvi is Business Leader of the yearThe low-key, but persistent, managing director of Sun Pharmaceutical Industries is a self-made billionaire.
- I’m not here to sack people, Dilip Shanghvi to Ranbaxy executivesRanbaxy country heads from different parts of the world had gathered in Delhi for their periodic performance review, and were in for a surp...
- Sun Pharma denies insider trading charges in Ranbaxy dealSun Pharma denied insider trading charges against Silverstreet Developers- its wholly owned arm - in the $4 bn acquisition deal of Ranbaxy ...
- Sun Pharma-Ranbaxy deal: We will guide Ranbaxy, says Dilip ShanghviShanghvi started his entrepreneurial dreams with a loan of Rs 10,000 from his father. It’s that same instinct that’s needed at Ranbaxy now,...
- Dilip Shanghvi, Sun Pharma promoter, a pharma maven with midas touchHis staff call him India's most aggressive promoter whose calm demeanour shadows his killer instincts when it comes to splurging on riskies...
- Ranbaxy deal fabulous for Sun Pharma: Ajay PiramalSun Pharma will be in a better position to manage Ranbaxy. They have handled overseas acquisitions successfully, says Ajay Piramal.
Load More
